DCGI slams Glenmark over misleading claims, price of COVID drug FabiFlu Ruchika Sharma20 July 2020 4:13 PM ISTMaking false claims without substantial clinical evidence in media is misleading to the patients and clinicians in such a global pandemic situation....
CONTROVERSY: DCGI exempts Biocon from Phase 3 trial of COVID drug Itolizumab, ICMR sees red Farhat Nasim17 July 2020 4:21 PM ISTBengaluru: In a major controversy, the exemption of biotechnology major Biocon from conducting Phase 3 trials of its psoriasis drug...
DCGI approves India first fully indigenously developed vaccine against pneumonia Farhat Nasim16 July 2020 1:00 PM ISTThe ministry said the vaccine will be used for active immunization against invasive disease and pneumonia caused by ''Streptococcus pneumonia'' among...
Zydus Cadila starts human trails of COVID-19 vaccine ZyCoV-D Ruchika Sharma16 July 2020 12:44 PM ISTSpeaking on the development, Chairman, Zydus Cadila, Mr. Pankaj R. Patel said, "This is an all-important step in our fight against COVID-19. We...
Biophore India gets DCGI nod to COVID drug Favipiravir Ruchika Sharma15 July 2020 12:05 PM ISTFavipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus,...
Biocon Itolizumab gets DCGI nod to treat COVID-19 patients Ruchika Sharma13 July 2020 1:28 PM ISTItolizumab will be manufactured and formulated as an intravenous injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru.
COVID Cure: DCGI approves Itolizumab for restricted emergency use Ruchika Sharma11 July 2020 2:43 PM ISTIt is for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
Serum Institute of India COVID vaccine anticipates DCGI nod by 2020 end Ruchika Sharma8 July 2020 1:16 PM ISTHe further said that till the vaccine comes, testing is the key and that is why SII has invested in MyLabs.
COVID-19: Mylan to launch Remdesivir at Rs 4800 per vial in India Ruchika Sharma7 July 2020 11:49 AM IST"The drug will be launched under the brand name 'Desrem' in India and will be available to patients in July at a price of Rs 4,800, which is more than...
AstraZeneca heart failure drug Dapagliflozin gets DCGI approval Ruchika Sharma6 July 2020 12:38 PM ISTThe company has received import and market permission from DCGI in Form CT-20 (Marketing Authorisation- Additional Indication). The receipt of the...
Zydus Cadila COVID-19 vaccine gets DCGI nod for human clinical trials Ruchika Sharma3 July 2020 11:08 AM ISTWith ZyCoV-D, the Company has successfully established the DNA vaccine platform in the country using non-replicating and a non-integrating plasmid...
FIRST: Bharat Biotech Covid-19 vaccine COVAXIN gets DCGI nod for human trials Ruchika Sharma30 Jun 2020 1:19 PM ISTThe collaboration with Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) was instrumental in the development of...
